EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

PCDHGB7 hypermethylation as a cancer-only marker: a multi-tumor formalin-fixed paraffin-embedded validation study in sex-specific and non-sex-specific tumors

Xiaolong Zou, Chao Wu, Hongyan Wei, Xilian Luo, Jiaying Deng, Wei Li

LabMed Discovery · 2026-11 · 100159

DOI: 10.1016/j.lmd.2026.100159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift LabMed Discovery, 2026-11. Verfasst von Xiaolong Zou und 5 weiteren Autor:innen. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

DNA methylation-based biomarkers have emerged as promising tools for cancer detection. Hypermethylated PCDHGB7 has been identified as a cancer-only marker, demonstrating hypermethylation across multiple tumor types in public databases. This study aimed to validate PCDHGB7 hypermethylation as a cancer only diagnostic biomarker across sex-specific and non-sex-specific tumors in a multi-tumor clinical formalin-fixed paraffin-embedded (FFPE) cohort by bisulfite pyrosequencing. However, independent validation outside the original discovery setting—and, in particular, any direct comparison between tumors arising in sex-specific organs and tumors arising in organs shared by both sexes—is still lacking.

Methods

FFPE tissue samples from four tumor types, comprising the sex-specific tumors prostate cancer and cervical cancer and the non-sex-specific tumors lung cancer and liver cancer, were collected from Harbin Medical University First Affiliated Hospital (2024–2026). PCDHGB7 methylation levels were quantified by bisulfite pyrosequencing. Methylation levels were compared between malignant and benign samples, and diagnostic performance was evaluated both at the pan-cancer fixed threshold (β≥0.589) and at tumor-specific Youden-optimal thresholds.

Results

Analysis of PCDHGB7 methylation across benign and tumor samples of varying ages in the The Cancer Genome Atlas (TCGA) database revealed that PCDHGB7 methylation is independent of age. Across 307 FFPE samples (78 malignant, 229 benign), PCDHGB7 was significantly hypermethylated in malignant tissues compared with benign ones across all four tumor types (all P

Zitieren

APA

Zou, X., Wu, C., Wei, H., Luo, X., Deng, J., & Li, W. (2026). PCDHGB7 hypermethylation as a cancer-only marker: a multi-tumor formalin-fixed paraffin-embedded validation study in sex-specific and non-sex-specific tumors. LabMed Discovery, 100159. https://doi.org/10.1016/j.lmd.2026.100159

Vancouver

Zou X, Wu C, Wei H, Luo X, Deng J, Li W. PCDHGB7 hypermethylation as a cancer-only marker: a multi-tumor formalin-fixed paraffin-embedded validation study in sex-specific and non-sex-specific tumors. LabMed Discovery. 2026:100159. doi:10.1016/j.lmd.2026.100159

BibTeX
@article{Zou2026,
  author = {Zou, Xiaolong and Wu, Chao and Wei, Hongyan and Luo, Xilian and Deng, Jiaying and Li, Wei},
  title = {PCDHGB7 hypermethylation as a cancer-only marker: a multi-tumor formalin-fixed paraffin-embedded validation study in sex-specific and non-sex-specific tumors},
  journal = {LabMed Discovery},
  year = {2026},
  pages = {100159},
  doi = {10.1016/j.lmd.2026.100159}
}
Kostenlos starten →